Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
GHRP-2
Growth Hormone Releasing Peptide-2, Pralmorelin
GHRP-6
Growth Hormone Releasing Peptide-6, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
A synthetic hexapeptide growth hormone secretagogue that stimulates GH release through the ghrelin receptor. Considered one of the most potent GHRPs available, producing stronger GH pulses than GHRP-6 but with more appetite stimulation than ipamorelin. Widely used in anti-aging and performance contexts.
One of the original synthetic growth hormone secretagogues, developed in the 1980s. A hexapeptide that strongly stimulates GH release through ghrelin receptor activation. Historically significant as the compound that led to the discovery of the ghrelin receptor and the development of the entire GHS drug class.
Binds to the growth hormone secretagogue receptor (GHS-R1a / ghrelin receptor) in the anterior pituitary, triggering GH release. Also stimulates appetite through hypothalamic ghrelin pathways. Produces a robust GH pulse that synergizes with GHRH analogs like CJC-1295 or sermorelin.
Binds to ghrelin receptors (GHS-R1a) in the pituitary and hypothalamus, triggering pulsatile GH release. Also stimulates appetite significantly through central ghrelin receptor activation — more so than most other GHS peptides. Increases IGF-1 levels downstream of GH release.
- Growth hormone optimization
- Muscle growth and recovery
- Anti-aging protocols
- Improved sleep quality
- Fat loss (via elevated GH)
- Growth hormone optimization
- Muscle recovery and growth
- Fat loss
- Appetite stimulation (useful in wasting conditions)
- Anti-aging protocols
- Increased appetite and hunger
- Water retention
- Elevated cortisol and prolactin (dose-dependent)
- Tingling or numbness at injection site
- Potential blood sugar effects
- Significant appetite stimulation (can undermine fat loss goals)
- Cortisol and prolactin elevation
- Water retention
- Desensitization with frequent dosing
- Tingling and numbness
- Limited long-term human safety data
Not FDA-approved. Available as a research chemical. Pralmorelin (the INN name) has been studied clinically in Japan for GH deficiency diagnosis but has no approved therapeutic indication in the US.
Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Available through licensed 503A compounding pharmacies with a physician prescription. Often used in combination with GHRH analogs like CJC-1295.
- Growth hormone-releasing peptides and their analogs
1998 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.